Benefit and risk of adding rivaroxaban in patients with coronary artery disease: A systematic review and meta‐analysis
Sign Up to like & getrecommendations! Published in 2020 at "Clinical Cardiology"
DOI: 10.1002/clc.23514
Abstract: Although the European Medicines Agency and the US Food and Drug Administration have, respectively, approved rivaroxaban for the prevention of recurrent major adverse cardiovascular events in patients with myocardial infarction and stable coronary artery disease,… read more here.
Keywords: risk adding; artery disease; coronary artery; benefit risk ... See more keywords